PAHO issued an epidemiological alert for the Americas on 10 February 2026, after 313,132 chikungunya cases across 18 countries in 2025 and a return of local transmission to Guyana, French Guiana, and Suriname after roughly a decade of silence. Here is what European travellers and public-health agencies should take from it.
For ten years, the chikungunya virus had gone quiet in Suriname, Guyana, and French Guiana. Then, in the first weeks of 2026, it returned. On 10 February, the Pan American Health Organization issued an epidemiological alert urging every country in the Americas to step up surveillance, laboratory testing, and integrated vector control. The reason, in plain numbers: the Americas recorded 313,132 chikungunya cases and 170 deaths across 18 countries in 2025, and a fresh wave is under way in territories that had been chikungunya-free for a decade.
If you live in Brussels or Bordeaux and you are planning a winter holiday in the Caribbean, this is the kind of news that ought to find its way to your kitchen table.
What PAHO actually said
The 10 February alert is short and unusually direct. The text begins by noting "a sustained increase in cases of chikungunya in countries and territories in the Americas Region" between late 2025 and early 2026, with "resumption of autochthonous transmission in areas that had not reported circulation of the virus for several years." PAHO/WHO then asks member states to do three things: intensify epidemiological and laboratory surveillance, ensure early detection and proper clinical management, and consolidate integrated vector control.
The headline figures, drawn from PAHO's own data and reported in its accompanying briefing, are these:
- 313,132 cases and 170 deaths in the Americas in 2025, across 18 countries.
- Renewed local transmission confirmed in Guyana, French Guiana, and Suriname, territories silent on chikungunya since the post-2014 epidemic faded.
These are not yet the numbers of a continental emergency. They are the numbers of a continental warning. The shape of the curve, not its height, is what worries epidemiologists. Sustained, multi-country, early-season transmission with new geographies coming online is the pattern that preceded the great 2014 chikungunya wave that crashed through the Caribbean and onward into Florida.
Why these three territories matter
The Guianas, Guyana, Suriname, and French Guiana, sit on the northern shoulder of South America, sharing a long coastal arc and a common ecology of Atlantic forest, coastal mangrove, and dense urban centres. Aedes aegypti, the mosquito that carries chikungunya, dengue, and Zika, is endemic across all three. So is the rainy season that traditionally precedes the worst transmission months.
What had been absent, for almost a decade, was the virus itself. After the 2014-2016 wave swept through the Americas, population immunity interrupted transmission for years. WHO notes that transmission is interrupted for several years where a high proportion of the population is infected and then immune. Ten years on, a new cohort of children, young adults, and recent migrants now lacks immunity. Add a viraemic traveller arriving on a single flight, and a new outbreak chain becomes possible almost overnight.
French Guiana is the variable that most concerns Europe. It is an overseas department of France, fully part of the European Union for legal and travel purposes, with regular direct flights to Paris-Orly. A traveller incubating chikungunya can step off a plane in mainland France the same day, well inside the virus's incubation window of 4 to 8 days (WHO). From there, every European territory where the tiger mosquito (Aedes albopictus) is established becomes a potential downstream node, and as of June 2025, the European Centre for Disease Prevention and Control's distribution map shows established albopictus populations in 369 NUTS-3 regions across 16 EU/EEA countries.
The disease itself, briefly
Chikungunya is a viral infection transmitted to humans through the bite of infected Aedes mosquitoes. According to the World Health Organization, the name comes from the Kimakonde language of southern Tanzania, where the first outbreak was described in 1952. It means, roughly, "to walk bent over", a description of the patient's posture during the acute phase, when joint pain becomes severe enough to make standing upright unbearable.
Symptoms usually appear 4 to 8 days after the bite of an infected mosquito. Most patients recover. A meaningful minority, however, develop a chronic post-chikungunya syndrome: joint pain that is often debilitating and may last for weeks, months or even years.
Two vaccines now exist, Valneva's Ixchiq and Bavarian Nordic's Vimkunya, and both are authorised in the European Union for people at risk. Ixchiq was the subject of an EMA safety review in 2025, and Vimkunya is under additional monitoring. They are not yet a tourist staple. The most reliable protection for the average traveller remains the most boring one: don't get bitten in the first place.
What this means for European travellers
Three things follow from PAHO's 10 February alert, even before any of us leaves the house.
First, the Caribbean and Guianas winter season is now a higher-risk environment for chikungunya than it was in 2024. Travellers heading from Europe to Suriname, French Guiana, Guyana, or any of the 18 countries and territories that reported cases in 2025 should treat this the way they would treat a yellow-fever country: with bite-prevention discipline as the baseline, and a clinician's number on the fridge in case of fever and joint pain on return.
Second, the risk of an imported case sparking an autochthonous European outbreak is non-trivial. France recorded 809 locally acquired chikungunya cases in 2025. The mosquitoes are already in place across the south of the EU. The only missing ingredient, in many summers, has been a critical mass of viraemic returnees. PAHO's data suggests that critical mass is now thicker than it was last spring.
Third, this is one more line in a longer story: arboviruses that used to be tropical curiosities are becoming continental neighbours. The right response is not panic. The right response is the boring set of habits, long sleeves at dusk, treated nets where you sleep, repellent on exposed skin, and emptying any standing water within five metres of where children play.
What to watch next
The next three months will tell us whether the 2026 alert is a blip or a wave. Watch in particular:
- PAHO's weekly chikungunya updates. A flat or falling curve in March, April is a good sign; sustained growth into the Caribbean rainy season is a bad one.
- The first autochthonous European chikungunya case of 2026. Whoever it lands in, Italy, France, or Spain, will own the EU news cycle for a week and reset every public-health agency's communication plan.
- ECDC's first 2026 European arbovirus monthly bulletin. It will be the first formal European read on whether the Americas wave is leaking northward.
- Vaccine uptake. With both Ixchiq and Vimkunya now on the market, and Ixchiq the subject of an EMA safety review in 2025, watch whether national travel-health authorities begin recommending them for high-risk Caribbean itineraries.
What we know
Sources cited
- Pan American Health Organization, "Epidemiological Alert: Chikungunya in the Region of the Americas," 10 February 2026, https://www.paho.org/en/documents/epidemiological-alert-chikungunya-10-february-2026
- Pan American Health Organization, "Chikungunya cases increasing in several countries in the Americas," 11 February 2026, https://www.paho.org/en/news/11-2-2026-chikungunya-cases-increasing-several-countries-americas-paho-recommends-preparedness
- World Health Organization, "Chikungunya" fact sheet, https://www.who.int/news-room/fact-sheets/detail/chikungunya
- European Centre for Disease Prevention and Control, "Chikungunya local transmission, previous years", https://www.ecdc.europa.eu/en/infectious-disease-topics/chikungunya-virus-disease/surveillance-and-updates/local-transmission-previous-years
- European Centre for Disease Prevention and Control, "Chikungunya virus disease, surveillance and updates", https://www.ecdc.europa.eu/en/chikungunya-virus-disease/surveillance-and-updates/seasonal-surveillance
- European Centre for Disease Prevention and Control, "Aedes albopictus, current known distribution," June 2025, https://www.ecdc.europa.eu/en/publications-data/aedes-albopictus-current-known-distribution-june-2025
- Santé publique France, "Chikungunya, données en France hexagonale", https://www.santepubliquefrance.fr/chikungunya/donnees-en-france-hexagonale
- European Medicines Agency, "Ixchiq (chikungunya vaccine), EPAR", https://www.ema.europa.eu/en/medicines/human/EPAR/ixchiq
- European Medicines Agency, "Vimkunya (chikungunya vaccine), EPAR", https://www.ema.europa.eu/en/medicines/human/EPAR/vimkunya
This article is general information, not medical advice. Ask a doctor or pharmacist about your own health.